Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that a pair of the data panels showing the results of Transwell invasion assays (specifically, the 'C4‑2 / shCON' and the PC‑3 / CON panels) featured in Fig. 3F on p. 927 contained overlapping sections, such that data that were intended to show the results from differently performed experiments appeared to have been derived from the same original source. The authors were able to re‑examine their original data files, and realized that this figure had been inadverently assembled incorrectly. The revised version of Fig. 3, containing the correct representative image of the PC‑3shCON group, is shown on the next page. The authors also noted that the statistics in Fig. 3G remained correct, and did not require correction on account of the error made in assembling this figure. Similarly, note that the correction made to this figure does not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this Corrigendum, and all the authors agree with its publication. They also apologize to the readership for any inconvenience caused. [Oncology Reports 45: 921‑932, 2021; DOI: 10.3892/or.2021.7920].

目的 探讨经尿道膀胱黏膜电切术联合塞来昔布治疗肠型腺性膀胱炎(CG)的有效性和安全性.方法 选取2019年1月至2021 年6月53例肠型CG患者作为研究对象,按照治疗方式的不同将其分为试验组(n=27,经尿道膀胱黏膜电切术联合塞来昔布治疗)和对照组(n=26,经尿道膀胱黏膜电切术治疗).比较两组的临床症状评分、术后复发情况及临床疗效.结果 术后1、3、6、9、12 个月,试验组的临床症状评分均低于术前(P＜0.05);术后 1、3、6、9、12 个月,试验组的临床症状评分低于对照组(P＜0.05).试验组的术后复发率明显低于对照组(P＜0.05).两组的手术均成功完成,无膀胱穿孔、围手术期大出血、输尿管狭窄等并发症发生.试验组的治疗总有效率明显高于对照组(P＜0.05).结论 经尿道膀胱黏膜电切术联合塞来昔布治疗肠型CG具有良好的临床效果,可降低疾病复发率.

Bladder cancer is the most common malignant tumor of the urinary system, and in China it is first among urogenital system tumors. More therapeutic targets are still urgently required to combat this disease. Lamin B2 (LMNB2) is a type of nuclear lamina filament protein, which is involved in multiple cellular processes, and known as an oncogene affecting the progression of multiple types of cancers. Although the multiple effects of LMNB2 on cancer progression have been elucidated, its possible role in bladder cancer remains unclear. In the present study, it was determined that LMNB2 expression was upregulated in human bladder cancer tissues, and its expression was correlated with the prognosis and the clinical features, including tumor stage (P=0.001) and recurrence (P=0.006) of patients with bladder cancer. In addition, it was further revealed that LMNB2 depletion inhibited bladder cancer cell proliferation, stimulated cell cycle arrest and apoptosis in vitro, and suppressed tumor growth of bladder cancer cells in mice. Furthermore, the present data revealed that LMNB2 promoted the proliferation of bladder cancer cells via transcriptional activation of CDCA3 expression. Therefore, the role of LMNB2 in bladder cancer progression was demonstrated, and may serve as a promising therapeutic target for bladder cancer treatment.

The aim of this study was to investigate the biological function and molecular mechanism of ARPC1A (actin related protein 2/3 complex subunit 1A) in prostate cancer progression. RT–qPCR and IHC results showed that the level of ARPC1A in prostate cancer tissues was significantly higher than that in adjacent tissues. The results of TCGA (the cancer genome atlas) database analysis showed that high expression of ARPC1A indicates poor prognosis in prostate cancer patients. In vitro functional experiments confirmed that downregulation of ARPC1A expression resulted in decreased cell viability and invasive ability of prostate cancer cells, as ARPC1A knockdown promoted ferroptosis. The transcriptional regulation mechanism of STAT3 (signal transduction and activators of transcription 3) on ARPC1A was elucidated by Co-IP, ChIP and luciferase reporter assays. In vivo experiments also supported the in vitro results. We propose that reduced ARPC1A expression inhibits prostate cancer cell viability and invasion in a ferroptotic manner. The ARPC1A level may serve as an independent predictor of prognosis in prostate cancer patients.

This study sought to provide contemporary data from a multi‐institution with respect to DNA‐repair genes (DRGs) status and its impact on effects of platinum‐based chemotherapy in treatment‐emergent neuroendocrine prostate cancer (t‐NEPC), for which little data exist.

Cell division cycle-associated 5 (CDCA5) can regulate cell cycle-related proteins to promote the proliferation of cancer cells. The purpose of the present study was to investigate the expression level of CDCA5 in prostate cancer (PCa) and its effect on PCa progression. The signalling pathway by which CDCA5 functions through was also attempted to elucidate. Clinical specimens of PCa patients were collected from the Second Hospital of Tianjin Medical University. The expression level of CDCA5 in cancer tissues and paracancerous tissues from PCa patients was detected by RT-qPCR analysis and IHC. The relationship between the expression level of CDCA5 and the survival rate of PCa patients was analysed using TCGA database. Two stable cell lines (C4-2 and PC-3) with CDCA5 knockdown were established, and the effects of CDCA5 on PCa cell proliferation were detected by MTT and colony formation assays. Flow cytometry was performed to detect the effect of CDCA5 on the PCa cell division cycle, and western blot analysis was used to determine changes in ERK phosphorylation levels after CDCA5 knockdown. The effect of CDCA5 expression on prostate tumour growth was assessed using a mouse xenograft model. The results revealed that the mRNA and protein expression levels of CDCA5 were significantly higher in PCa tissues than in paracancerous tissues. High CDCA5 expression was associated with the prognosis of patients with PCa. CDCA5 expression knockdown significantly reduced the number of PCa cells in mitoses and inhibited their proliferation in vitro and in vivo. When CDCA5 was knocked down, the phosphorylation level of ERK was also reduced. Collectively, CDCA5 was upregulated and affected the prognosis of patients with PCa. Decreased CDCA5 expression inhibited PCa cell proliferation by inhibiting the ERK signalling pathway. Thus, CDCA5 may be a potential therapeutic target for PCa.

Purpose. KIF20A is essential in the process of spindle assembly and cytokinesis regulation. The role of KIF20A during tumorigenesis and tumor development has been well studied in several cancers. But the association between the KIF20A clinical role and prostate cancer (PCa) has not been reported yet. In this study, we investigated its potential prognostic effect and its role in progression of prostate cancer. Methods. Real-time quantitative polymerase chain reaction and Western blots were used to investigate the KIF20A transcription and translation levels in 7 pairs of fresh PCa tissue and adjacent normal prostate tissue. Immunohistochemistry (IHC) was used to investigate the KIF20A protein level in 114 PCa tissue samples. Bioinformatics analysis was performed to analyze the effect of KIF20A in oncologic prognosis in PCa patients. MTT assay, transwell assay, and colony formation assay in vitro and tumor formation assay in vivo were performed to evaluate the biological behavior of KIF20A in prostate cancer. Results. KIF20A was significantly elevated in tumor tissue compared with normal prostate tissue at both the mRNA and the protein level. High expression of KIF20A at the protein level was correlated with adverse clinicopathological features. Bioinformatics analysis showed that the high KIF20A expression group has a poor biochemical recurrence- (BCR-) free survival. Knocking down KIF20A suppressed the proliferation, migration, and invasion of the prostate cancer cell both in vitro and in vivo. Conclusions. Our data demonstrated that the high expression of KIF20A was associated with poor clinical outcome and targeting KIF20A could reduce proliferation, migration, and invasion of the prostate cancer cell, indicating that KIF20A might be a potential prognostic and therapeutic target for PCa patients.

目的:对比分析后腹腔镜与输尿管镜技术对感染性输尿管上段结石取石碎石的临床效果.方法:选取我院收治的120例感染性输尿管上段结石患者进行研究,以随机数字表法将患者分为两组,输尿管镜组采用输尿管镜技术治疗,后腹腔镜组患者采用后腹腔镜手术治疗,对比两组治疗效果.结果:输尿管镜组患者结石直径、手术时间、住院时间均明显小于后腹腔镜组(p＜0.05);但腹腔镜组患者结石清除率及术后并发症发生率均明显优于输尿管镜组(p＜0.05).结论:采用后腹腔镜切开取石术治疗感染性输尿管上段结石患者具有结石清除率高、术后并发症少等优点,对于感染性输尿管上段结石患者较为适用.

Objective To investigate the causes of urinary tract infection in the patients with transurethral bladder tumor resection(TURBT),and to explore the preventive measures.Methods A retrospective investigation method to the patients with TURBT and other relevant clinical data were performed.Results 92 patients in the postoperative indwelling urine bacterial culture was positive in 41 cases,the total incidence rate of 44.6％;a total of 45 strains of pathogenic bacteria,there were 10 strains of gram-positive cocci,accounted for 22.2％;35 strains of gram-negative bacilli,accounted for 77.8％;the main strain were Klebsiella pneumoniae,Escherichia coli and Enterococcus,not detected fungi;after TURBT,urinary tract infections caused by a very complex reasons,operation itself involved in the 2 consecutive invasive operation-TURBT surgery and catheterization,was the most important factor,in addition to elderly patients,patients with diabetes,multiple tumor sites,operation had indwelling catheter were performed after TURBT susceptible to infection.Conclusion The operation full aseptic operation,equipment,strict disinfection gauze operation,operation process to prevent tissue damage of mucosa,select the appropriate catheter indwelling catheter position,ensure appropriate,properly placed and fixed catheter,ensure its smooth,strengthen the treatment of other diseases,can effectively reduce the urinary tract after TURBT infection.

Objective To analyze clinical effect of large adrenal tumor resection by retroperitoneoscopy in lateral position and half-lateral position. Methods A total of 90 patients with large adrenal tumor resection by retroperitoneoscopy were divided by admission order into observation group and control group, with 45 cases in each group.The observation group received half-lateral position treatment, and control group received lateral position treatment. Surgical effect was compared between two groups. Results The observation group had transfer rate of open surgery as 0, canula increasing rate as 2.2%, hospital stays as (5.1±0.9)d, intraoperative blood loss as(55.2±16.8)ml, and operation time as (58.1±16.3)min, which were better than 17.8%, 31.1%, (7.6±1.3)d, (80.2±33.9)ml and (95.4±28.2)min in control group, and differences had statistical significance(P<0.05). Conclusion Large adrenal tumor resection by retroperitoneoscopy in half-lateral position proves better clinical treatment effect than lateral position, and it is worth clinical promotion and application.

目的：研究输尿管镜治疗妊娠期肾绞痛的安全性和有效性。方法选择69例妊娠期肾绞痛患者为研究对象，对其临床治疗资料进行回顾性分析。结果所有患者均顺利完成治疗，临床症状得到明显改善，且治疗期间，无1例患者出现输尿管穿孔等严重并发症。同时，发生先兆流产者5例，经对症治疗后，症状明显改善，2例患者早产，其余67例患者均顺利完成分娩。结论临床上运用输尿管镜治疗妊娠期肾绞痛，能够明显改善患者的症状，并且并发症少，具有较高的安全性和有效性，值得运用推广。

目的:探究介入疗法在肾错构瘤出血中的治疗价值.材料与方法:择取2012年8月到2014年9月这两年间于笔者所在医院以介入疗法治疗肾错构瘤出血的病患共20例,设为研究组;择取同期于我院以开放手术进行治疗的肾错构瘤出血病患20例,设为对照组.对比两组患者的相关治疗指标.结果:研究组患者在抗生素用药时间、患者住院时间、术中出血量、手术时间上均优于对照组,甚至其并发症率也远远低于对照组,P ＜0.05,统计学有差异.结论:介入疗法微创、并发症少,术后不易复发,更具临床治疗价值.

目的 分析临床肾肿瘤患者行后腹腔镜肾部分切除术的效果.方法 调查对象从我院2010年2月~2014年5月接收肾肿瘤患者中抽选(共60例),将其分成不同临床处理组,即:对照组(开放肾部分切除术处理)、研究组(后腹腔镜肾部分切除术处理),预后对疾病效果进行评定.结果 研究组患者预后并发症发生率为3.3%,和对照组的20.0%相比较低,两者有区别(P<0.05).并且两组肾肿瘤患者手术时间、出血量、住院时间等围术期指标有区别(P<0.05).结论 临床针对肾肿瘤患者行后腹腔镜肾部分切除术作用突出,可加快康复进度,减少并发症,值得借鉴.

目的 探讨巨大肾肿瘤的诊断与治疗.方法 10例患者术前都经过B超、CT、MRI、KUB+IVP等检查明确为肾实质性占位,肿瘤均>7 cm,行根治性肾癌手术,术后继续给予生物免疫治疗.结果 随访3～72个月,5例至今存活;2例3个月死亡,1例半年死亡,1例1年死亡,1例1年半死亡.结论 肾肿瘤通过临床症状及影像学检查术前明确诊断.根治性肾肿瘤切除术是巨大肾肿瘤的主要治疗方法,术后生物免疫治疗对预防肿瘤转移有效.

目的 探讨前列腺汽化电切术后插管困难的原因及处理方法.方法 对我院2005～2010年收治的34例前列腺汽化电切术后插管困难,采用新方法置管技巧的患者进行回顾性分析.结果 34例均为II度、III度前列腺增生患者,多以中叶增生为主,采用新方法置管简单、方便、出血少,术后疗效满意,未出现严重的并发症.结论 前列腺汽化电切术后插管困难,采用新的插管方法首选安全.